新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Sci. Transl. Med.:新基因疗法治疗心脏衰竭

Sci. Transl. Med.:新基因疗法治疗心脏衰竭

来源:生物谷 2013-11-14 14:09

2013年11月14日讯 /生物谷BIOON/--西奈山医学院心血管专家对大动物心脏衰竭模型实施了基因治疗,该疗法的成效显著。相关报道发表在近期的Science Translational Medicine杂志上。该研究检测了SUMO-1基因疗法,该研究是临床前实验的最后阶段。

之前基因治疗针对的是SERCA2基因,一期和二期临床效果都很好,而Hajjar 博士在2011年的Nature文章称在人类心衰病人中SUMO-1基因也降低,而SUMO-1调节SERCA2a的活性,即不改变SERCA2a水平的情况下增强蛋白质的功能。之后在小鼠模型中的的研究发现针对SUMO-1基因治疗显著提高心脏功能。

于是本次研究中,科学家检测了分别针对SUMO-1基因,SERCA2基因的基因治疗和两基因结合的疗法的效果。

在大动物心衰模型中,科学家发现单纯转运高剂量的SUMO-1和,同时转运SUMO-1、SERCA2都会增强心脏收缩力,增加血流,减小心脏体积。

Hajjar博士称,该新研究表明SUMO-1对SERCA2的功能实施有重要作用。针对SUMO-1的基因替代疗法将会有效的治疗心衰病人。(生物谷Bioon.com)

SUMO-1 Gene Transfer Improves Cardiac Function in a Large-Animal Model of Heart Failure

Lisa Tilemann, Ahyoung Lee, Kiyotake Ishikawa, Jaume Aguero, Kleopatra Rapti, Carlos Santos-Gallego, Erik Kohlbrenner, Kenneth M. Fish, Changwon Kho and Roger J. Hajjar

Recently, the impact of small ubiquitin-related modifier 1 (SUMO-1) on the regulation and preservation of sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA2a) function was discovered. The amount of myocardial SUMO-1 is decreased in failing hearts, and its knockdown results in severe heart failure (HF) in mice. In a previous study, we showed that SUMO-1 gene transfer substantially improved cardiac function in a murine model of pressure overload–induced HF. Toward clinical translation, we evaluated in this study the effects of SUMO-1 gene transfer in a swine model of ischemic HF. One month after balloon occlusion of the proximal left anterior descending artery followed by reperfusion, the animals were randomized to receive either SUMO-1 at two doses, SERCA2a, or both by adeno-associated vector type 1 (AAV1) gene transfer via antegrade coronary infusion. Control animals received saline infusions. After gene delivery, there was a significant increase in the maximum rate of pressure rise [dP/dt(max)] that was most pronounced in the group that received both SUMO-1 and SERCA2a. The left ventricular ejection fraction (LVEF) improved after high-dose SUMO-1 with or without SERCA2a gene delivery, whereas there was a decline in LVEF in the animals receiving saline. Furthermore, the dilatation of LV volumes was prevented in the treatment groups. SUMO-1 gene transfer therefore improved cardiac function and stabilized LV volumes in a large-animal model of HF. These results support the critical role of SUMO-1 in SERCA2a function and underline the therapeutic potential of SUMO-1 for HF patients.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库